Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Right on target: eradicating leukemic stem cells.

Daniela S Krause1, Richard A Van Etten

  • 1Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

Trends in Molecular Medicine
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.

Blood advances·2026
Same author

A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.

ACS chemical biology·2026
Same author

MyD88 in myeloid cells drives angiotensin II-induced vascular inflammation, is associated with prevalent heart failure, and predicts all-cause mortality in arterial hypertension.

European heart journal open·2026
Same author

DNA-protein cross-links promote cGAS-STING-driven premature aging and embryonic lethality.

Science (New York, N.Y.)·2026
Same author

R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2025
Same journal

Hyocholic acids: Third bile acids for neonatal health.

Trends in molecular medicine·2026
Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
See all related articles

New research highlights the critical role of leukemia stem cells (LSCs) in acute myeloid leukemia (AML) relapse. Targeting these rare LSCs offers a promising strategy for achieving a permanent cure for AML patients.

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunology

Background:

  • Acute myeloid leukemia (AML) has a low cure rate, with less than a third of adult patients achieving remission with current therapies.
  • Leukemia stem cells (LSCs) are rare, stem-like cells responsible for disease initiation and relapse in AML.
  • LSCs can transfer the disease to immunodeficient mice, confirming their role in AML pathogenesis.

Purpose of the Study:

  • To review recent advancements in understanding leukemia stem cell (LSC) biology in acute myeloid leukemia (AML).
  • To discuss novel therapeutic strategies aimed at specifically targeting and eliminating LSCs.
  • To emphasize the necessity of LSC eradication for achieving a permanent cure in AML.

Main Methods:

  • Review of recent scientific literature on LSC research.

Related Experiment Videos

  • Analysis of signaling pathways involved in the LSC phenotype.
  • Evaluation of antibody-based approaches for LSC elimination.

    • Main Results:

    • Recent studies have elucidated key signaling pathways driving the LSC phenotype.
    • Novel therapeutic approaches using antibodies to target LSCs have been described.
    • Understanding LSC biology is crucial for developing effective AML treatments.

    Conclusions:

    • Eradication of leukemia stem cells (LSCs) is essential for a permanent cure in acute myeloid leukemia (AML).
    • Targeting LSCs represents a promising novel therapeutic strategy for AML.
    • Continued research into LSC biology and targeted therapies is critical for improving patient outcomes.